Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy

Cancer Treatment Reviews

Volumn 31, Issue 2, 2005, Pages 90-105

  Kweekel, D M ^a   Gelderblom, H ^a   Guchelaar, H J ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Colorectal; Oxaliplatin; Pharmacogenetic; Polymorphism; SNP

Indexed keywords

CALCIUM; CARBOPLATIN; CELL PROTEIN; CISPLATIN; CORTICOSTEROID; DNA; DOPAMINE RECEPTOR STIMULATING AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GLUTATHIONE TRANSFERASE; IRINOTECAN; MAGNESIUM; MANNITOL; NEDAPLATIN; OXALIPLATIN; PLATINUM DERIVATIVE; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; PROTEIN TYROSINE KINASE INHIBITOR; RNA; SATRAPLATIN; SEROTONIN ANTAGONIST; UNCLASSIFIED DRUG; X RAY REPAIR CROSS COMPLEMENTING PROTEIN 1; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

ANTINEOPLASTIC ACTIVITY; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DNA ADDUCT; DNA DAMAGE; DNA REPAIR; DNA REPLICATION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME SYNTHESIS; EVIDENCE BASED MEDICINE; EXCISION REPAIR; GENETIC POLYMORPHISM; GENETIC TRANSCRIPTION; HEMATOLOGIC DISEASE; HUMAN; INDIVIDUALIZATION; LETHALITY; LEUKOPENIA; METABOLIC INHIBITION; METASTASIS; MISMATCH REPAIR; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; OTOTOXICITY; PERIPHERAL NEUROPATHY; PHARMACODYNAMICS; PHARMACOGENOMICS; REVIEW; RNA SYNTHESIS; SENSORY NEUROPATHY; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 17444422174     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrv.2004.12.006     Document Type: Article

References (81)

1. Frei Holland Cancer Medicine vol. 1 2003 BC Becker Inc Hamilton (Ont.)
2. M. van Glabbeke J. Renard H.M. Pinedo F. Cavalli J. Vermorken C. Sessa et al. Iproplatin and carboplatin induced toxicities: Overview of phase II clinical trial conducted by the EORTC Early Clinical Trials Cooperative Group (ECTG) Eur J Cancer Clin Oncol 24 1988 255-262
3. A.M. Di Francesco A. Ruggiero R. Riccardi Cellular and molecular aspects of drugs of the future: Oxaliplatin Cell Mol Life Sci 59 2002 1914-1927
4. F. Grolleau L. Gamelin M. Boisdron-Celle B. Lapied M. Pelhate E. Gamelin A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels J Neurophysiol 85 2001 2293-2297
5. L. Gamelin M. Boisdron-Celle R. Delva V. Guerin-Meyer N. Ifrah A. Morel et al. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: A retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer Clin Cancer Res 10 2004 4055-4061
6. M.J. McKeage T. Hsu D. Screnci G. Haddad B.C. Baguley Nucleolar damage correlates with neurotoxicity induced by different platinum drugs Br J Cancer 85 2001 1219-1225
7. F. Levi G. Metzger C. Massari G. Milano F. Levi M. Mishima et al. Oxaliplatin: Pharmacokinetics and chronopharmacological aspects Clin Pharmacokinet Jan 5 2000 1-21PMID
8. M. Kobayashi P.A. Wood W.J. Hrushesky Circadian chemotherapy for gynecological and genitourinary cancers Chronobiol Int 19 2002 237-251
9. N.A. Boughattas F. Levi C. Fournier B. Hecquet G. Lemaigre A. Roulon et al. Stable circadian mechanisms of toxicity of two platinum analogs (cisplatin and carboplatin) despite repeated dosages in mice J Pharmacol Exp Ther 255 1990 672-679
10. M.L. Rothenberg A.M. Oza R.H. Bigelow J.D. Berlin J.L. Marshall R.K. Ramanathan et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: Interim results of a phase III trial J Clin Oncol 21 2003 2059-2069
11. A. de Gramont A. Figer M. Seymour M. Homerin A. Hmissi J. Cassidy et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer J Clin Oncol 18 2000 2938-2947
12. T. Andre C. Boni L. Mounedji-Boudiaf M. Navarro J. Tabernero T. Hickish et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer N Engl J Med 350 2004 2343-2351
13. R.M. Goldberg D.J. Sargent R.F. Morton C.S. Fuchs R.K. Ramanathan S.K. Williamson et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer J Clin Oncol 22 2004 23-30
14. L.J. van Warmerdam Tailor-made chemotherapy for cancer patients Neth J Med 51 1997 30-35
15. T. Van Gelder D.A. Hesselink R.M. Van Hest R.A. Mathot R. Van Schaik Pharmacogenetics in immunosuppressive therapy: The best thing since TDM? Ther Drug Monit 26 2004 343-346
16. H.L. McLeod J. Yu Cancer pharmacogenomics: SNPs, chips, and the individual patient Cancer Invest 21 2003 630-640
17. B. Desoize C. Madoulet M.A. Graham G.F. Lockwood D. Greenslade S. Brienza et al. Particular aspects of platinum compounds used at present in cancer treatment Crit Rev Oncol Hematol 1077 2002 317-325PMID
18. C.R. Culy D. Clemett L.R. Wiseman Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies Drugs 60 2000 895-924
19. Sanofi Synthelabo the Netherlands. Prod Info Eloxatin; 2004
20. J. Liu E. Kraut J. Bender R. Brooks S. Balcerzak M. Grever et al. Pharmacokinetics of oxaliplatin (NSC 266046) alone and in combination with paclitaxel in cancer patients Cancer Chemother Pharmacol 49 2002 367-374
21. M.A. Graham G.F. Lockwood D. Greenslade S. Brienza M. Bayssas E. Gamelin et al. Clinical pharmacokinetics of oxaliplatin: A critical review Clin Cancer Res 1066 2000 205-218PMID
22. A.H. Calvert M.J. Egorin Carboplatin dosing formulae: Gender bias and the use of creatinine-based methodologies Eur J Cancer 38 2002 11-16
23. J.A. Mello S.J. Lippard J.M. Essigmann DNA adducts of cis-diamminedichloroplatinum(II) and its trans isomer inhibit RNA polymerase II differentially in vivo Biochemistry 34 1995 14783-14791
24. E. Raymond S. Faivre S. Chaney J. Woynarowski E. Cvitkovic Cellular and molecular pharmacology of oxaliplatin Mol Cancer Ther 2002 227-235
25. H.J. Guchelaar A. Vermes I. Vermes C. Haanen Apoptosis: Molecular mechanisms and implications for cancer chemotherapy Pharm World Sci 19 1997 119-125
26. M. Mishima G. Samimi A. Kondo X. Lin S.B. Howell S. Hector et al. The cellular pharmacology of oxaliplatin resistance Eur J Cancer 1176 2002 1405-1412PMID
27. S. Akiyama Z.S. Chen T. Sumizawa T. Furukawa Resistance to cisplatin Anticancer Drug Des 14 1999 143-151
28. S.G. Chaney A. Vaisman Specificity of platinum-DNA adduct repair J Inorg Biochem 77 1999 71-81
29. Z.Z. Zdraveski J.A. Mello C.K. Farinelli J.M. Essigmann M.G. Marinus MutS preferentially recognizes cisplatin- over oxaliplatin-modified DNA J Biol Chem 277 2002 1255-1260
30. B.C. Broughton A. Cordonnier W.J. Kleijer N.G. Jaspers H. Fawcett A. Raams et al. Molecular analysis of mutations in DNA polymerase eta in xeroderma pigmentosum-variant patients Proc Natl Acad Sci USA 99 2002 815-820
31. S. Arnould I. Hennebelle P. Canal R. Bugat S. Guichard Cellular determinants of oxaliplatin sensitivity in colon cancer cell lines Eur J Cancer 2003 112-119
32. A. Hartwig H. Blessing T. Schwerdtle I. Walter Modulation of DNA repair processes by arsenic and selenium compounds Toxicology 193 2003 161-169
33. S. Shall G. de Murcia Poly(ADP-ribose) polymerase-1: What have we learned from the deficient mouse model? Mutat Res 460 2000 1-15
34. E.J. Duell J.K. Wiencke T.J. Cheng A. Varkonyi Z.F. Zuo T.D. Ashok et al. Polymorphisms in the DNA repair genes XRCC1 and ERCC2 and biomarkers of DNA damage in human blood mononuclear cells Carcinogenesis 2000 965-971
35. M.R. Shen I.M. Jones H. Mohrenweiser et al. Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans Cancer Res 1 1998 604-608
36. M.R. Shen M.Z. Zdzienicka H. Mohrenweiser L.H. Thompson M.P. Thelen Mutations in hamster single-strand break repair gene XRCC1 causing defective DNA repair Nucleic Acids Res 26 1998 1032-1037
37. J. Stoehlmacher V. Ghaderi S. Iobal S. Groshen D. Tsao-Wei D. Park et al. A polymorphism of the XRCC1 gene predicts for response to platinum based treatment in advanced colorectal cancer Anticancer Res 21 2001 3075-3079
38. R.M. Lunn R.G. Langlois L.L. Hsieh C.L. Thompson D.A. Bell XRCC1 polymorphisms: Effects on aflatoxiri Bl-DNA adducts and glycophorin A variant frequency Cancer Res 59 1999 2557-2561
39. Charles J, Monzo M, Artells R, Amat R, Foro P, Fuster D, et al. XPC, XPD/ ERCC2, UMPS, Cyp1b1 and XRCC5 single nucleotide polymorphisms in head and neck cancer. In: Asco proceedings 2004 general poster session, 5588; 2004
40. Sarries C, Alberola V, De Las Penas R, Camps C, Massuti B, Garcia-Gomez R, et al. Combined DNA repair gene single nucleotide polymorphisms in gemcitabine/cisplatin-treated non-small-cell lung cancer patients. In: Asco proceedings 2004 poster discussion, 7031; 2004
41. M.R. Spitz X. Wu Y. Wang L.E. Wang S. Shete C.I. Amos et al. Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients Cancer Res 61 2001 1354-1357
42. D.J. Park J. Stoehlmacher W. Zhang D.D. Tsao-Wei S. Groshen H.J. Lenz A xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer Cancer Res Dec. 15 2001 8654-8658
43. T. Bessho D. Mu A. Sancar Initiation of DNA interstrand cross-link repair in humans: The nucleotide excision repair system makes dual incisions 5′ to the cross-linked base and removes a 22- to 28-nucleotide-long damage-free strand Mol Cell Biol 17 1997 6822-6830
44. T. Bessho A. Sancar L.H. Thompson M.P. Thelen Reconstitution of human excision nuclease with recombinant XPF-ERCC1 complex J Biol Chem 272 1997 3833-3837
45. J.T. Reardon A. Vaisman S.G. Chaney A. Sancar Efficient nucleotide excision repair of cisplatin, oxaliplatin, and bis-aceto-ammine-dichloro-cyclohexylamine-platinum(IV) (IV) (JM216) platinum intrastrand DNA diadducts Cancer Res Aug. 15 1999 3968-3971
46. E.M. Taylor B.C. Broughton E. Botta M. Stefanini A. Sarasin N.G. Jaspers et al. Xeroderma pigmentosum and trichothiodystrophy are associated with different mutations in the XPD (ERCC2) repair/transcription gene Proc Natl Acad Sci USA 94 1997 8658-8663
47. T. Kobayashi I. Kuraoka M. Saijo Y. Nakatsu A. Tanaka Y. Someda et al. Mutations in the XPD gene leading to xeroderma pigmentosum symptoms Hum Mutat 9 1997 322-331
48. B.C. Broughton A.F. Thompson S.A. Harcourt W. Vermeulen J.H. Hoeijmakers E. Botta et al. Molecular and cellular analysis of the DNA repair defect in a patient in xeroderma pigmentosum complementation group D who has the clinical features of xeroderma pigmentosum and Cockayne syndrome Am J Hum Genet 56 1995 167-174
49. Ricardi U, Regazzoni S, Ghio P, Giachino D, De Marchi M, Novello S, et al. The K751Q polymorphism of XPD gene in lung cancer patients receiving platinum-based chemotherapy. In: Asco proceedings 2004 integrated education session, 2500; 2004
50. Glasgow SC, Yu J, Lineham DC, Watson MA, McLeod HL. Modeling the response of colorectal cancer to common chemotherapy using multivariate gene expression. In: Asco proceedings 2004 oral presentation, 2008; 2004
51. M. Dabholkar F. Bostick-Bruton C. Weber V.A. Bohr C. Egwuagu E. Reed ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients J Natl Cancer Inst 84 1992 1512-1517
52. D. Murray E. Rosenberg The importance of the ERCC1/ERCC4[XPF] complex for hypoxic-cell radioresistance does not appear to derive from its participation in the nucleotide excision repair pathway Mutat Res 364 1996 217-226
53. B.S. Andersson T. Sadeghi M.J. Siciliano R. Legerski D. Murray Nucleotide excision repair genes as determinants of cellular sensitivity to cyclophospharnide analogs Cancer Chemother Pharmacol 38 1996 406-416
54. K.V. Ferry T.C. Hamilton S.W. Johnson Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: Role of ERCC1-XPF Biochem Pharmacol 60 2000 1305-1313
55. R.E. Meyn S.F. Jenkins L.H. Thompson Defective removal of DNA cross-links in a repair-deficient mutant of Chinese hamster cells Cancer Res 42 1982 3106-3110
56. J. Boyer E.G. McLean S. Aroori P. Wilson A. McCulla P.D. Carey et al. Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan Clin Cancer Res 10 2004 2158-2167
57. M.D. Chipchase M. O'Neill D.W. Melton Characterization of premature liver polyploidy in DNA repair (Ercc1)-deficient mice Hepatology 38 2003 958-966
58. J. Me Whir J. Selfridge D.J. Harrison S. Squires D.W. Melton Mice with DNA repair gene (ERCC-1) deficiency have elevated levels of p53, liver nuclear abnormalities and die before weaning Nat Genet 5 1993 217-224
59. J.J. Yu K.B. Lee C. Mu Q. Li T.V. Abernathy F. Bostick-Bruton et al. Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene Int J Oncol 16 2000 555-560
60. D. Park J. Stoehlmacher H.J. Lenz ERCC1 polymorphism associated with ERCC1 mRNA expression Proc Am Assoc Cancer Res 43 2002 1591 [abstr.]
61. Y. Shirota J. Stoehlmacher J. Brabender Y.P. Xiong H. Uetake K.D. Danenberg et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy J Clin Oncol 19 2001 4298-4304
62. H.J. Lenz Pharmacogenomics in colorectal cancer Semin Oncol 30 2003 47-53
63. R. Metzger C.G. Leichman K.D. Danenberg P.V. Danenberg H.J. Lenz K. Hayashi et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy J Clin Oncol 16 1998 309-316
64. M. Mukai A. Kanzaki Z.S. Chen H. Miyashita T. Sumizawa T. Furukawa et al. Enhanced nucleotide excision repair in cisplatin resistant human KB carcinoma cells Oncol Rep 9 2002 839-844
65. F. Fan C. Liu S. Tavare N. Arnheim Polymorphisms in the human DNA repair gene XPF Mutat Res 406 1999 115-120
66. Y. Matsumura C. Nishigori T. Yagi S. Imamura H. Takebe Characterization of molecular defects in xeroderma pigmentosum group F in relation to its clinically mild symptoms Hum Mol Genet 7 1998 969-974
67. T.R. Smith E.A. Levine N.D. Perrier M.S. Miller R.I. Freimanis K. Lohman et al. DNA-repair genetic polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev 12 2003 1200-1204
68. P.C. Ng S. Henikoff SIFT: Predicting amino acid changes that affect protein function Nucleic Acids Res 31 2003 3812-3814
69. P.C. Ng S. Henikoff Accounting for human polymorphisms predicted to affect protein function Genome Res 12 2002 436-446
70. M.A. Watson R.K. Stewart G.B. Smith T.E. Massey D.A. Bell Human glutathione S-transferase polymorphisms: Relationship to lung tissue enzyme activity and population frequency distribution Carcinogenesis 19 1998 275-280
71. J. Stoehlmacher D.J. Park W. Zhang S. Groshen D.D. Tsao-Wei M.C. Yu et al. Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer J Natl Cancer Inst 94 2002 936-942
72. 105Val polymorphism Cancer Res 60 2000 5621-5624
73. J. Stoehlmacher D.J. Park W. Zhang D. Yang S. Groshen S. Zahedy et al. A multivariate analysis of genomic polymorphisms: Prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer Br J Cancer 91 2004 344-354
74. E.S. Kirn F.R. Khuri R.S. Herbst Epidermal growth factor receptor biology (IMC-C225) Curr Opin Oncol 13 2001 506-513
75. Magné N, Pereira S, Etienne MC, Formento JL, Francoual M, Demard F, et al. Analysis of the dinucleotide repeat polymorphism in the epidermal growth factor receptor (EGFR) in tumor and normal tissue of head and neck cancer patients. In: Asco proceedings 2004 poster session, 5518; 2004
76. J. Mendelsohn J. Baselga Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer J Clin Oncol 21 2003 2787-2799
77. J.M. Xu A. Azzariti M. Severino B. Lu G. Colucci A. Paradiso Characterization of sequence-dependent synergy between ZD1839 ("Iressa") and oxaliplatin Biochem Pharmacol 66 2003 551-563
78. D.A. Notterman U. Alon A.J. Sierk A.J. Levine Transcriptional gene expression profiles of colorectal adenoma, adenocarcinoma, and normal tissue examined by oligonucleotide arrays Cancer Res 61 2001 3124-3130
79. Gurubhagavatula S, Zhou W, Park S, Neuberg DS, Lynch TJ, Wain JC, et al. Nucelotide excisionrepair gene haplotypes and advanced non-small cell lung cancer prognosis. In: Asco proceedings 2004, 3040; 2004
80. H.L. McLeod D.J. Sargent S. Marsh C.S. Fuchs R.K. Ramanathan S.K. Williamson et al. Pharmacogenetic analysis of systemic toxicity and response after 5-fluorouracil (5FU)/CPT-11, 5FU/oxaliplatin (oxal), or CPT-11/oxal therapy for advanced colorectal cancer (CRC): Results from an intergroup trial Proc Am Soc Clin Oncol 22 2003 253 [abstract 1013]
81. R.H. Mathijssen S. Marsh M.O. Karlsson R. Xie S.D. Baker J. Verweij et al. Irinotecan pathway genotype analysis to predict pharmacokinetics Clin Cancer Res 9 2003 3246-3253